Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 948,623 shares, a decrease of 98.9% from the August 31st total of 82,633,317 shares. Based on an average daily trading volume, of 186,993 shares, the short-interest ratio is currently 5.1 days. Approximately 33.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Eaton Financial Holdings Company LLC acquired a new position in Gossamer Bio during the 4th quarter worth about $44,000. Caitong International Asset Management Co. Ltd increased its stake in Gossamer Bio by 22.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock worth $82,000 after purchasing an additional 4,771 shares during the period. ProShare Advisors LLC increased its stake in Gossamer Bio by 39.6% during the fourth quarter. ProShare Advisors LLC now owns 45,338 shares of the company’s stock worth $141,000 after purchasing an additional 12,863 shares during the period. Rockefeller Capital Management L.P. lifted its position in shares of Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after purchasing an additional 50,666 shares in the last quarter. Finally, AXQ Capital LP lifted its position in shares of Gossamer Bio by 36.1% during the fourth quarter. AXQ Capital LP now owns 63,117 shares of the company’s stock worth $196,000 after purchasing an additional 16,750 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on GOSS shares. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Stock Down 0.5%

NASDAQ GOSS traded down $0.06 on Thursday, reaching $10.93. The stock had a trading volume of 236,070 shares, compared to its average volume of 210,656. The stock has a fifty day moving average price of $13.02 and a two-hundred day moving average price of $19.53. Gossamer Bio has a 12-month low of $9.10 and a 12-month high of $309.60. The firm has a market capitalization of $32.02 million, a price-to-earnings ratio of -0.20 and a beta of 2.00.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: Gossamer Bio submitted a New Drug Application to the U.S. Food and Drug Administration for seralutinib, its lead candidate for pulmonary arterial hypertension. The filing represents a major development milestone and could improve the company’s long-term commercial prospects if accepted and ultimately approved. Gossamer Bio Submits New Drug Application to the FDA
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised several longer-term EPS forecasts, including estimates for 2027 through 2029. The revisions suggest the analyst expects improving financial performance as seralutinib advances toward potential commercialization. Gossamer Bio analyst estimates
• Neutral Sentiment: Reports on September short interest are contradictory: one cites a sharp decline to 948,623 shares, while another reports zero shares short. The figures may reflect a reporting or corporate-action issue, so investors should verify the data before interpreting it as evidence of covering or short-squeeze potential.
• Negative Sentiment: Despite the NDA milestone, reports indicated that Gossamer Bio’s stock fell following the FDA filing, suggesting a possible “sell-the-news” reaction or investor disappointment with the filing’s near-term impact. The company remains dependent on regulatory progress and has yet to generate commercial revenue. Gossamer Bio stock falls after FDA filing
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast, as well as estimates for the fourth quarter of 2026 and first quarter of 2027. Although the firm remains bullish overall, the revisions highlight continued substantial losses and financing risk while Gossamer funds development.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.